SGTX Sigilon Therapeutics

Sigilon Therapeutics to Present at the Needham Virtual Healthcare Conference

Sigilon Therapeutics to Present at the Needham Virtual Healthcare Conference

CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for acute and chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will present a corporate overview during the Needham Virtual Healthcare Conference. The presentation will take place on Thursday, April 20, 2023 at 10:15 a.m. EDT.

A webcast of the presentation will be accessible through the investor section of the company’s website at , with a replay available for 90 days following the event.

About Sigilon Therapeutics

Sigilon Therapeutics seeks to develop functional cures for patients with a broad range of acute and chronic diseases by harnessing the power of the human cell through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates are non-viral engineered cell-based therapies designed to produce a wide range of functions or therapeutic molecules that may be missing or deficient in patients living with diseases such as diabetes. The engineered cells are encapsulated by Sigilon’s Afibromer™ biomaterials matrix, which is designed to shield them from immune rejection. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.

Investor Contact

Robert Windsor, Jr., J.D.

VP, Head of Investor Relations

Sigilon Therapeutics

617-586-3837

Media Contact

Amy Bonanno

Solebury Strategic Communications



914-450-0349

 



EN
18/04/2023

Underlying

SGTXSigilon Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sigilon Therapeutics

 PRESS RELEASE
Free
SGTX Sigilon Therape...

Sigilon Announces Reverse Stock Split of Common Stock

Sigilon Announces Reverse Stock Split of Common Stock CAMBRIDGE, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (Nasdaq: SGTX) today announced it will effect a one-for-13 reverse stock split of its issued and outstanding common stock. Sigilon stockholders approved an amendment to Sigilon’s Fifth Amended and Restated Certificate of Incorporation to effect the reverse stock split at Sigilon’s Annual Meeting of Stockholders held on May 19, 2023. The reverse stock split is intended to increase the per share trading price of Sigilon’s common stock to enable Sigilon to satis...

May 22, 2023 1 EN
 PRESS RELEASE
Free
SGTX Sigilon Therape...

Sigilon Therapeutics Reports First Quarter 2023 Financial Results and ...

Sigilon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights SIG-002, Sigilon’s lead program for the treatment of diabetes, transitioning to IND-enabling and NHP studies in the second half of 2023 Pipeline prioritization extends anticipated cash runway into 2025 CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today reported financial results for the first quarter ended March 31, ...

May 9, 2023 1 EN
 PRESS RELEASE
Free
SGTX Sigilon Therape...

Sigilon Therapeutics to Present at the Needham Virtual Healthcare Conf...

Sigilon Therapeutics to Present at the Needham Virtual Healthcare Conference CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for acute and chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will present a corporate overview during the Needham Virtual Healthcare Conference. The presentation will take place on Thursday, April 20, 2023 at 10:15 a.m. EDT. A webcast of the present...

April 18, 2023 1 EN
 PRESS RELEASE
Free
SGTX Sigilon Therape...

Sigilon Therapeutics Reports Fourth Quarter and Full Year 2022 Financi...

Sigilon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights Advancing IND-enabling activities for lead program in diabetes, SIG-002, with plans to conduct non-human primate studies in second half of 2023 SIG-002 demonstrated efficacy and durability in in vivo mouse models for up to 17 weeks Extended anticipated cash runway into 2025 CAMBRIDGE, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Ther...

March 14, 2023 1 EN
 PRESS RELEASE
Free
SGTX Sigilon Therape...

Sigilon Therapeutics Reports Third Quarter 2022 Financial Results and ...

Sigilon Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights Identified important optimization features for its platform to mitigate PFO risks in current and future programs Advanced iPS cell differentiation protocol for the diabetes program in preparation for anticipated IND-enabling studies in 2023 Continued optimization of the MPS-1 program, with plans to initiate IND-enabling studies in the second half of 2023 CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to devel...

November 10, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch